SCHEMBL23640595

SCHEMBL23640595

CCCCCCC(CCCCCC)CCCNC=O

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 6/20 0.72
ADH1B P00325 4/20 0.72
ADH1A P07327 4/20 0.72
ADH7 P40394 4/20 0.72
ADH1C P00326 3/20 0.72
ADH4 P08319 2/20 0.72
LMNA P02545 1/20 0.48
TSHR P16473 3/20 0.41
ALDH1A1 P00352 2/20 0.41
FAAH O00519 2/20 0.38
TRPV1 Q8NER1 1/20 0.38
CYP3A4 P08684 1/20 0.38
GNAI3 P08754 1/20 0.37
GNAO1 P09471 1/20 0.37
GNAI1 P63096 1/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
DAGLA Q9Y4D2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8043725 1.00 EPHX1 (0.72) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL23640543 0.98 ADH1B (0.69) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL23640389 0.98 EPHX1 (0.75) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL23640558 0.96 ADH1B (0.72) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL19996858 0.90 ADH1B (0.63) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL19415950 0.90 ADH1B (0.61) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL305123 0.85 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL9658779 0.85 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL302735 0.85 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C
SCHEMBL4879688 0.85 EPHX1 (1.00) EPHX1ADH1BADH1AADH7ADH1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2022-04-14 US disclosed
US-20210214316-A1 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2021-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210214316-A1 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS NCOA1, NCOR1, NCOA3 EPHX1 4120/4885ADH1B 3100/4885ADH1A 2575/4885
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 EPHX1 4454/4885ADH1B 3554/4885ADH1A 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.